Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products

Drugs in R and D

Volumn 15, Issue 1, 2015, Pages 1-9

  Frevert, Jürgen ^a  

^a Merz Pharmaceuticals GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADVERSE EFFECTS; ANIMAL; COMPARATIVE STUDY; ESTHETIC SURGERY; HUMAN; MOLECULAR WEIGHT;

ANIMALS; BOTULINUM TOXINS, TYPE A; COSMETIC TECHNIQUES; HUMANS; MOLECULAR WEIGHT; NEUROMUSCULAR AGENTS;

EID: 84965089483     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0077-1     Document Type: Article

References (88)

1. Azzalure (Ipsen, Paris). Summary of product characteristic (SPC). [WWW document]. http://emc.medicines.org.uk/medicine/21985. Accessed 17 Dec 2014.
2. Bocouture (Merz Pharmaceuticals GmbH, Frankfurt). Summary of product characteristic (SPC). [WWW document]. https://www.medicines.org.uk/emc/medicine/23251. Accessed 17 Dec 2014.
3. Botox (Allergan Inc, Irvine). Summary of product characteristic (SPC). [WWW document]. https://www.medicines.org.uk/emc/medicine/20564. Accessed 17 Dec 2014.
4. Dysport (Ipsen, Paris). Summary of product characteristics (SPC). [WWW document]. http://emc.medicines.org.uk/medicine/870/SPC/Dysport/. Accessed 17 Dec 2014.
5. Vistabel (Allergan Inc, Irvine). Summary of product characteristic (SPC). [WWW document]. https://www.medicines.org.uk/emc/medicine/17580. Accessed 17 Dec 2014.
6. Xeomin (Merz Pharmaceuticals GmbH, Frankfurt). Summary of product characteristic (SPC). [WWW document]. https://www.medicines.org.uk/emc/medicine/20666. Accessed 17 Dec 2014.
7. International Society of Aesthetic Plastic Surgeons. ISAPS International Survey on Aesthetic/Cosmetic Procedures Performed in 2013. http://www.isaps.org/news/isaps-global-statistics. Last accessed August 2014.
8. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949–51.
9. Roggenkamper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303–12.
10. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines. Dermatol Surg. 2010;36(Suppl 4):2146–54.
11. Prager W, Wissmuller E, Kollhorst B, Williams S, Zschocke I. Comparison of two botulinum toxin type A preparations for treating crow’s feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg. 2010;36(Suppl 4):2155–60.
12. Benecke R, Hauschke D, Roggenkämper P. IncobotulinumtoxinA demonstrated therapeutic equivalence to onabotulinumtoxinA in the treatment of blepharospasm and cervical dystonia. J Neurol Sci. 2013;333:e120.
13. Dressler D, Mander G, Fink K. Measuring the potency labelling of onabotulinumtoxinA (Botox((R))) and incobotulinumtoxinA (Xeomin ((R))) in an LD50 assay. J Neural Transm. 2012;119:13–5.
14. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67:669–83.
15. Pagan FL, Harrison A. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin(R): a new botulinum neurotoxin A. Parkinsonism Relat Disord. 2012;18:441–5.
16. Jandhyala R. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence. J Drugs Dermatol. 2012;11:731–6.
17. Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci. 2013;34:1043–8.
18. Carruthers J, Fournier N, Kerscher M, Ruiz-Avila J, Trindade de Almeida AR, Kaeuper G. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine—a global, evidence-based botulinum toxin consensus education initiative: part II: incorporating botulinum toxin into aesthetic clinical practice. Dermatol Surg. 2013;39:510–25.
19. Lorenc ZP, Kenkel JM, Fagien S, et al. Consensus Panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet Surg J. 2013;33:35S–40S.
20. Poulain B, Trevidic P, Clave M, et al. Clinical equivalence of conventional OnabotulinumtoxinA (900 KDa) and IncobotulinumtoxinA (neurotoxin free from complexing proteins—150 KDa): 2012 multidisciplinary French consensus in aesthetics. J Drugs Dermatol. 2013;12:1434–46.
21. Hambleton P, Pickett AM. Potency equivalence of botulinum toxin preparations. J R Soc Med. 1994;87:719.
22. Sesardic D, Leung T, Gaines Das R. Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin. Biologicals. 2003;31:265–76.
23. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin serotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol. 2001;8(Suppl 5):21–9.
24. Poulain B, Lonchamp E, Jover E, Popoff MR, Molgo J. Mecanismes d’action des toxines et neurotoxines botuliques. [Mechanisms of action of botulinum toxins and neurotoxins]. Ann Dermatol Venereol. 2009;136(Suppl 4):S73–6.
25. Brunger AT, Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon. 2009;54:550–60.
26. Popoff MR, Poulain B. Bacterial toxins and the nervous system: neurotoxins and multipotential toxins interacting with neuronal cells. Toxins (Basel). 2010;2:683–737.
27. Inoue K, Fujinaga Y, Watanabe T, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun. 1996;64:1589–94.
28. Krebs KM, Lebeda FJ. Comparison of the structural features of botulinum neurotoxin and NTNH, a non-toxic accessory protein of the progenitor complex. Botulinum J. 2008;1:116–34.
29. Panjwani N, O’Keeffe R, Pickett A. Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. Botulinum J. 2008;1:153–66.
30. Lietzow MA, Gielow ET, Le D, Zhang J, Verhagen MF. Subunit stoichiometry of the Clostridium botulinum type A neurotoxin complex determined using denaturing capillary electrophoresis. Protein J. 2008;27:420–5.
31. Eisele KH, Fink K, Vey M, Taylor HV. Studies on the dissociation of botulinum neurotoxin type A complexes. Toxicon. 2011;57:555–65.
32. Frevert J. Content of botulinum neurotoxin in Botox(R)/Vistabel(R), Dysport(R)/Azzalure(R), and Xeomin(R)/Bocouture(R). Drugs R D. 2010;10:67–73.
33. DasGupta BR, Boroff DA. Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration. J Biol Chem. 1968;243:1065–72.
34. Sharma SK, Ramzan MA, Singh BR. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon. 2003;41:321–31.
35. Chen F, Kuziemko GM, Stevens RC. Biophysical characterization of the stability of the 150-kilodalton botulinum toxin, the nontoxic component, and the 900-kilodalton botulinum toxin complex species. Infect Immun. 1998;66:2420–5.
36. Gu S, Rumpel S, Zhou J, et al. Botulinum neurotoxin is shielded by NTNHA in an interlocked complex. Science. 2012;335:977–81.
37. Lee K, Zhong X, Gu S, et al. Molecular basis for disruption of E-cadherin adhesion by botulinum neurotoxin A complex. Science. 2014;344:1405–10.
38. Gu S, Jin R. Assembly and function of the botulinum neurotoxin progenitor complex. Curr Top Microbiol Immunol. 2013;364:21–44.
39. Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Ther Lett. 2008;13:1–4.
40. Park J, Lee MS, Harrison AR. Profile of Xeomin(R) (incobotulinumtoxinA) for the treatment of blepharospasm. Clin Ophthalmol. 2011;5:725–32.
41. Goodnough MC, Johnson EA. Stabilization of botulinum toxin type A during lyophilization. Appl Environ Microbiol. 1992;58:3426–8.
42. Carey WD. Incorrect reconstitution of incobotulinumtoxinA leads to loss of neurotoxin. J Drugs Dermatol. 2014;13:735–8.
43. Niamtu J 3rd. Neurotoxin waste from drawing product through the vial stopper. J Clin Aesthet Dermatol. 2014;7:33–7.
44. 0.9 % w/v Sodium Chloride (B. Braun Melsungen AG). Summary of product characteristics (SPC). [WWW document]. http://www.mhra.gov.uk/home/groups/spcpil/documents/spcpil/con1411106022485.pdf. Accessed 17 Dec 2014.
45. Adler S, Bicker G, Bigalke H, et al. The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. The report and recommendations of a ZEBET Expert Meeting. Altern Lab Anim. 2010;38:315–30.
46. Pickett A. Consistent biochemical data are essential for comparability of botulinum toxin type A products. Drugs R D. 2011;11:97–8.
47. Sesardic D. Is it possible to accurately determine content of botulinum neurotoxin type A in drug products? Drugs R D. 2010;10:91–2.
48. Hunt T, Clarke K. Potency evaluation of a formulated drug product containing 150-kd botulinum neurotoxin type A. Clin Neuropharmacol. 2009;32:28–31.
49. Bigalke H. Properties of pharmaceutical products of botulinum neurotoxins. In: Jankovic J, Albanese A, Atassi MZ, et al., editors. Botulinum toxin: therapeutic clinical practice and science. Philadelphia (PA): Saunders Elsevier; 2009. p. 389–97.
50. Pickett A. Dysport: pharmacological properties and factors that influence toxin action. Toxicon. 2009;54:683–9.
51. Aoki KR, Ranoux D, Wissel J. Using translational medicine to understand clinical differences between botulinum toxin formulations. Eur J Neurol. 2006;13(Suppl 4):10–9.
52. Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg. 2007;33:S37–43.
53. Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34:52–9.
54. Brodsky MA, Swope DM, Grimes D. Diffusion of botulinum toxins. Tremor Other Hyperkinet Mov (NY). 2012;2.
55. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Comparison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304:155–61.
56. Wohlfarth K, Wegner F, Bigalke H, Rummel A. The role of human serum albumin and neurotoxin associated proteins in the formulation of different BoNT/A products. Poster presented at the Toxins 2012 conference, Miami Beach, Florida, USA, 5–8 December 2012 Botulinum J. 2012;2:208–361.
57. Grein S, Mander GJ, Fink K. Stability of botulinum neurotoxin type A, devoid of complexing proteins. Botulinum J. 2011;2:49–58.
58. Frevert J. Xeomin is free from complexing proteins. Toxicon. 2009;54:697–701.
59. Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm. 2013;120:275–90.
60. Borodic G. Immunologic resistance after repeated botulinum toxin type a injections for facial rhytides. Ophthal Plast Reconstr Surg. 2006;22:239–40.
61. Lee SK. Antibody-induced failure of botulin toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg. 2007;33(1 Spec No):S105–S10.
62. Dressler D, Wohlfahrt K, Meyer-Rogge E, Wiest L, Bigalke H. Antibody-induced failure of botulinum toxin A therapy in cosmetic indications. Dermatol Surg. 2010;36(Suppl 4):2182–7.
63. Stengel G, Bee EK. Antibody-induced secondary treatment failure in a patient treated with botulinum toxin type A for glabellar frown lines. Clin Interv Aging. 2011;6:281–4.
64. Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2013;7:11–7.
65. Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations on botulinum neurotoxin A in the rabbit. Neurotox Res. 2006;9:238.
66. Kukreja R, Chang TW, Cai S, et al. Immunological characterization of the subunits of type A botulinum neurotoxin and different components of its associated proteins. Toxicon. 2009;53:616–24.
67. Wang L, Sun Y, Yang W, Lindo P, Singh BR. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon. 2014;82:52–60.
68. Sharon N, Lis H. History of lectins: from hemagglutinins to biological recognition molecules. Glycobiology. 2004;14:53R–62R.
69. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. Biochem Soc Trans. 2008;36:1478–81.
70. Sharma SK, Singh BR. Immunological properties of Hn-33 purified from type A Clostridium botulinum. J Nat Toxins. 2000;9:357–62.
71. Bryant AM, Cai S, Singh BR. Comparative immunochemical characteristics of botulinum neurotoxin type A and its associated proteins. Toxicon. 2013;72:126–32.
72. Dressler D, Adib Saberi F. New formulation of Botox: complete antibody-induced treatment failure in cervical dystonia. J Neurol Neurosurg Psychiatry. 2007;78:108–9.
73. Benecke R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs. 2012;26:e1–9.
74. Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008;70:133–6.
75. Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009;32:213–8.
76. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther. 2007;29:683–90.
77. Brin MF, Comella CL, Jankovic J, Lai F. Naumann M; CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord. 2008;23:1353–60.
78. Schulte-Baukloh H, Bigalke H, Miller K, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol. 2008;15:407–15.
79. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res. 2009;31:463–6.
80. Muller K, Mix E, Adib Saberi F, Dressler D, Benecke R. Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009;116:579–85.
81. ®) across multiple indications. Mov Disord. 2010;25:2211–8.
82. Dressler D. Complete secondary botulinum toxin therapy failure in blepharospasm. J Neurol. 2000;247:809–10.
83. ®)). J Neural Transm. 2014;121:769–71.
84. Dressler D. Five-year experience with incobotulinumtoxinA (Xeomin((R))): the first botulinum toxin drug free of complexing proteins. Eur J Neurol. 2012;19:385–9.
85. Hefter H, Hartmann C, Kahlen U, Moll M, Bigalke H. Prospective analysis of neutralising antibody titres in secondary non-responders under continuous treatment with a botulinumtoxin type A preparation free of complexing proteins—a single cohort 4-year follow-up study. BMJ Open. 2012;2.
86. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl 8):S92–100.
87. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213–7.
88. Herrmann J, Geth K, Mall V, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol. 2004;55:732–5.